Hutchison China MediTechの売上総利益
Hutchison China MediTechの売上総利益 は何ですか。
Hutchison China MediTech Ltd.の売上総利益 は18.08%です。
売上総利益 の定義は何ですか。
売上総利益は、売上と商品の売上原価との差を収益で除してパーセンテージで表したものです。
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
LSEのセクタHealth Careにおける売上総利益 の企業と比べるHutchison China MediTech
Hutchison China MediTechは何をしますか。
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTechと類似の売上総利益
- Xlife Sciences Ag Sf 1の売上総利益 は18.06%です。
- Senior Plcの売上総利益 は18.06%です。
- Leggett & Plattの売上総利益 は18.07%です。
- Ye Xingの売上総利益 は18.07%です。
- Rosier SAの売上総利益 は18.08%です。
- Deutsche Post AGの売上総利益 は18.08%です。
- Hutchison China MediTechの売上総利益 は18.08%です。
- BorgWarner Incの売上総利益 は18.09%です。
- Wuhan General (China)の売上総利益 は18.09%です。
- Value Partnersの売上総利益 は18.09%です。
- Value Partnersの売上総利益 は18.09%です。
- Fauvet-Girelの売上総利益 は18.09%です。
- Man Yue Technologyの売上総利益 は18.11%です。